Mary Wilson
Well-known member
JAMA. Published online February 12, 2021. doi:10.1001/jama.2021.1967
Tom T. Shimabukuro, MD, MPH, MBA[SUP]1[/SUP]; Matthew Cole, MPH[SUP]2[/SUP]; John R. Su, MD, PhD, MPH[SUP]1[/SUP]
In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for 2 mRNA-based vaccines for prevention of coronavirus disease 2019 (COVID-19): Pfizer-BioNTech COVID-19 vaccine (EUA issued December 11; 2 doses, 3 weeks apart) and Moderna COVID-19 vaccine (EUA issued December 18; 2 doses, 1 month apart). Shortly after each authorization, the Advisory Committee on Immunization Practices issued interim recommendations for use.[SUP]1,2
... [/SUP]Following implementation of vaccination, cases of anaphylaxis after administration of the Pfizer-BioNTech and Moderna vaccines began to be reported.[SUP]3[/SUP][SUP],4[/SUP] Anaphylaxis is a life-threatening allergic reaction that can occur after vaccination, with onset typically within minutes to hours.[SUP]5[/SUP] The initial estimated reporting rates for anaphylaxis in the US were 11.1 cases per million doses administered of the Pfizer-BioNTech vaccine (December 14-23, 2020) and 2.5 cases per million doses administered of the Moderna vaccine (December 21, 2020-January 10, 2021).[SUP]3,4
https://jamanetwork.com/journals/jama/fullarticle/2776557?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=021721#.YC1dS2P4D-I.twitter[/SUP]
Tom T. Shimabukuro, MD, MPH, MBA[SUP]1[/SUP]; Matthew Cole, MPH[SUP]2[/SUP]; John R. Su, MD, PhD, MPH[SUP]1[/SUP]
In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for 2 mRNA-based vaccines for prevention of coronavirus disease 2019 (COVID-19): Pfizer-BioNTech COVID-19 vaccine (EUA issued December 11; 2 doses, 3 weeks apart) and Moderna COVID-19 vaccine (EUA issued December 18; 2 doses, 1 month apart). Shortly after each authorization, the Advisory Committee on Immunization Practices issued interim recommendations for use.[SUP]1,2
... [/SUP]Following implementation of vaccination, cases of anaphylaxis after administration of the Pfizer-BioNTech and Moderna vaccines began to be reported.[SUP]3[/SUP][SUP],4[/SUP] Anaphylaxis is a life-threatening allergic reaction that can occur after vaccination, with onset typically within minutes to hours.[SUP]5[/SUP] The initial estimated reporting rates for anaphylaxis in the US were 11.1 cases per million doses administered of the Pfizer-BioNTech vaccine (December 14-23, 2020) and 2.5 cases per million doses administered of the Moderna vaccine (December 21, 2020-January 10, 2021).[SUP]3,4
https://jamanetwork.com/journals/jama/fullarticle/2776557?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=021721#.YC1dS2P4D-I.twitter[/SUP]